.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Quest Diagnostics recently raised its 2026 profit and revenue forecasts. This update reflects a resilient diagnostic testing demand across both routine and advanced clinical categories. Consequently, the New Jersey-based provider reported first-quarter results that surpassed previous Wall Street expectations. Shares rose significantly as investors reacted to the positive financial outlook.
Healthcare providers are currently navigating a phase of post-pandemic normalization. Therefore, many companies lean on hospital laboratory management deals to maintain steady volumes. Quest recorded a 9.4% revenue increase for its largest business segment. Furthermore, organic requisition volumes increased by over 10% during this period. This growth persists even while the industry faces sustained reimbursement pressures and rising labor costs.
Beyond routine screenings, advanced diagnostic tools show substantial market growth. Specifically, blood tests used to identify Alzheimer's disease are gaining significant traction. Also, tests for cardiometabolic and endocrine conditions reported double-digit revenue increases. These trends highlight a growing clinical focus on early detection of chronic conditions. The company expects to continue this momentum throughout the fiscal year.
Q1: Why did Quest Diagnostics raise its 2026 forecast?
The company cited resilient demand for routine diagnostic testing and significant growth in advanced diagnostics as primary drivers for the upgraded outlook.
Q2: Which specialty testing areas showed the most growth?
Quest reported double-digit revenue growth in advanced diagnostics, specifically in blood tests for Alzheimer's, cardiometabolic conditions, and endocrine disorders.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Quest Diagnostics raises 2026 profit and revenue forecasts due to resilient demand for routine diagnostic testing and advanced screening for Alzheimer's....
4 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
